Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database

Surgery

Volumn 141, Issue 6, 2007, Pages 828-829

  de Pont, Anne Cornélie J M ^a   Bakx, Roel ^a   Boermeester, Marja A ^a   Schultz, Marcus J ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ABDOMINAL INFECTION; APACHE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION RISK; LETTER; LUNG INFECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURGICAL MORTALITY; SURGICAL PATIENT;

ANTI-INFECTIVE AGENTS; DATABASES, FACTUAL; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RISK ASSESSMENT; SEPSIS; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 34249847310     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.01.015     Document Type: Letter

References (8)

1. Payen D., Sablotzki A., Barie P.S., Ramsay G., Lowry S., Williams M., et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 140 (2006) 726-739
2. Bernard G.R., Wesley E., Wright T.J., Fraiz J., Stasek J.E., Russell J.A., et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29 (2001) 2051-2059
3. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al., The PROWESS study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
4. Vincent J.L., Bernard G.R., Beale R., Doig C., Putensen C., Dhainaut J.F., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266-2277
5. Abraham E., Naum C., Bandi V., Gervich D., Lowry S.F., Wunderink R., et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phoslpholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 31 (2003) 718-728
6. Zeiher B.G., Steingrub J., Laterre P.F., Dimitrienko A., Fukiishi Y., Abraham E., and The EZZI Study Group. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phoslpholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 33 (2005) 1741-1748
7. Barie P.S., Williams M.D., McCollam J.S., Bates B.M., Qualy R.L., Lowry S.F., et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 188 (2004) 212-220
8. Assmann S.F., Pocock S.J., Enos L.E., and Kasten L.E. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 (2000) 1064-1069